Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

© The Author(s) 2022 Open Access This article is licensed under a Creative Commons Attri- bution 4.0 International License, which permits use, sharing, adapta- tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source...

Full description

Bibliographic Details
Main Author: Brannagan, Thomas H. (author)
Other Authors: Coelho, Teresa (author), Wang, Annabel K. (author), Polydefkis, Michael J. (author), Dyck, Peter J. (author), Berk, John L. (author), Drachman, Brian (author), Gorevic, Peter (author), Whelan, Carol (author), Conceição, isabel (author), Plante-Bordeneuve, Violaine (author), Merlini, Giampaolo (author), Obici, Laura (author), Plana, Josep Maria Campistol (author), Gamez, Josep (author), Kristen, Arnt V. (author), Mazzeo, Anna (author), Gentile, Luca (author), Narayana, Arvind (author), Olugemo, Kemi (author), Aquino, Peter (author), Benson, Merrill D. (author), Gertz, Morie (author)
Format: article
Language:eng
Published: 2022
Subjects:
Clinical trial
Familial amyloid polyneuropathy
Hereditary transthyretin amyloidosis
Inotersen
Peripheral neuropathies
Polyneuropathy
Online Access:http://hdl.handle.net/10451/54413
Country:Portugal
Oai:oai:repositorio.ul.pt:10451/54413

Internet

http://hdl.handle.net/10451/54413

Similar Items